Taysha Gene Therapies to Participate in Upcoming September Investor Healthcare Conferences

Rhea-AI Summary

Taysha Gene Therapies (NASDAQ: TSHA) announced its participation in multiple investor healthcare conferences in September 2021, including Citi’s 16th Annual BioPharma Conference and the Morgan Stanley Global Healthcare Conference. Key dates include September 8 for Citi, September 9 at 5:00 pm ET for Morgan Stanley, and several others leading up to September 27. The company's leadership will participate in various formats such as 1x1 meetings and fireside chats, showcasing their commitment to advancing gene therapies for monogenic CNS diseases.

Citi’s 16^th Annual BioPharma Conference on September 8, 2021

Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021 at 5:00 pm ET

2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 at 1:20 pm ET

HC Wainwright 23^rd Annual Global Investment Conference on September 13, 2021 at 7:00 am ET

SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines on September 23, 2021

2021 Cantor Virtual Global Healthcare Conference on September 27, 2021 at 8:00 am ET

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the following investor healthcare conferences: Citi’s 16^th Annual BioPharma Conference, Morgan Stanley 19th Annual Global Healthcare Conference, 2021 Wells Fargo Virtual Healthcare Conference, HC Wainwright 23^rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference and the SVB Leerink CybeRx Series.

Conferences Details:

Event:		Citi’s 16th Annual BioPharma Conference
Date:		Wednesday September 8, 2021
Format:		1x1 meetings
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer
		Kimberly Lee, SVP, Corporate Communications and Investor Relations

Event:		Morgan Stanley 19th Annual Global Healthcare Conference
Date:		Thursday September 9, 2021
Time:		5:00 pm ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

Event:		2021 Wells Fargo Virtual Healthcare Conference
Date:		Friday September 10, 2021
Time:		1:20 pm ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

Event:		HC Wainwright 23rd Annual Global Investment Conference
Date:		Monday September 13, 2021
Time:		7:00 am ET
Format:		Fireside chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

Event:		SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicine
Date:		Thursday September 23, 2021
Format:		1x1 meetings
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer
		Kimberly Lee, SVP, Corporate Communications and Investor Relations

Event:		2021 Cantor Virtual Global Healthcare Conference
Date:		Monday September 27, 2021
Time:		8:00 am ET
Format:		Fireside Chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005994/en/

Company Contact:

Kimberly Lee, D.O.

SVP, Corporate Communications and Investor Relations

Taysha Gene Therapies

klee@tayshagtx.com

Media Contact:

Carolyn Hawley

Canale Communications

carolyn.hawley@canalecomm.com

Source: Taysha Gene Therapies, Inc.

FAQ

What conferences is Taysha Gene Therapies participating in September 2021?

Taysha Gene Therapies is participating in Citi’s 16th Annual BioPharma Conference on September 8, Morgan Stanley 19th Annual Global Healthcare Conference on September 9, and others through September 27.

When is the Morgan Stanley Global Healthcare Conference for Taysha Gene Therapies?

The Morgan Stanley 19th Annual Global Healthcare Conference will take place on September 9, 2021, at 5:00 pm ET.

What is the focus of Taysha Gene Therapies at the conferences?

Taysha Gene Therapies will focus on advancing AAV-based gene therapies for treating monogenic diseases of the central nervous system.

Where can I find webcasts of Taysha Gene Therapies conferences?

Webcasts for Taysha Gene Therapies conferences will be available in the 'Events & Media' section of their corporate website.

What is the significance of the events for Taysha Gene Therapies?

These events allow Taysha Gene Therapies to showcase their advancements and engage with investors regarding their pivotal-stage gene therapies.